Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and zollinger-ellison syndrome long-term outcome of a more virulent form of HPT

Annals of Surgery

Volumn 247, Issue 3, 2008, Pages 501-510

  Norton, Jeffrey A ^a   Venzon, David J ^b   Berna, Marc J ^c   Alexander, H R ^d   Fraker, Douglas L ^e   Libutti, Stephen K ^b   Marx, Stephen J ^f   Gibril, Fathia ^c   Jensen, Robert T ^c  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; FEMALE; FOLLOW UP; HUMAN; HYPERPLASIA; MALE; MULTIPLE ENDOCRINE NEOPLASIA; NEPHROLITHIASIS; PARATHYROIDECTOMY; PATHOLOGY; PRIMARY HYPERPARATHYROIDISM; PROSPECTIVE STUDY; RECURRENT DISEASE; TREATMENT OUTCOME; ZOLLINGER ELLISON SYNDROME;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, PRIMARY; HYPERPLASIA; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEPHROLITHIASIS; PARATHYROIDECTOMY; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; ZOLLINGER-ELLISON SYNDROME;

EID: 42249096146     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31815efda5     Document Type: Article

References (71)

1. Arnalsteen LC, Alesina PF, Quiereux JL, et al. Long-term results of less than total parathyroidectomy for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery. 2002;132:1119 -1124; discussion 1124- 1125.
2. Burgess JR, David R, Parameswaran V, et al. The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg. 1998;133:126 -129.
3. Marx SJ, Simonds WF, Agarwal SK, et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res. 2002;17(Suppl 2):N37-N43.
4. Marx SJ, Menczel J, Campbell G, et al. Heterogeneous size of the parathyroid glands in familial multiple endocrine neoplasia type 1. Clin Endocrinol. 1991;35:521-526.
5. Malmaeus J, Benson L, Johansson H, et al. Parathyroid surgery in the multiple endocrine neoplasia type 1 syndrome: choice of surgical procedure. World J Surg. 1986;10:668-672.
6. Lee CH, Tseng LM, Chen JY, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 1: individualized management with low recurrence rates. Ann Surg Oncol. 2006;13:103-109.
7. Hubbard JG, Sebag F, Maweja S, et al. Subtotal parathyroidectomy as an adequate treatment for primary hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg. 2006;141:235-239.
8. Hubbard JG, Sebag F, Maweja S, et al. Primary hyperparathyroidism in MEN 1 - how radical should surgery be? Langenbecks Arch Surg. 2002;386:553-557.
9. Katai M, Sakurai A, Ikeo Y, et al. Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: comparison with sporadic parathyroid adenomas. Horm Metab Res. 2001;33:499 -503.
10. Kraimps JL, Duh QY, Demeure M, et al. Hyperparathyroidism in multiple endocrine neoplasia syndrome. Surgery. 1992;112:1080 -1086.
11. Prinz RA, Gamvros O, Sellu D, et al. Subtotal parathyroidectomy for primary chief cell hyperplasia of the multiple endocrine neoplasia type 1 syndrome. Ann Surg. 1981;193:26 -29.
12. Proye C, Carnaille B, Quievreux JL, et al. Late outcome of 304 consecutive patients with multiple gland enlargement in primary hyperparathyroidism treated by conservative surgery. World J Surg. 1998;22: 526-529; discussion 529-530.
13. Proye C. [Surgical treatment of primary hyperparathyroidism during MEN1 and other genetically determined forms]. Ann Ital Chir. 2003; 74:417- 422.
14. Elaraj DM, Skarulis MC, Libutti SK, et al. Results of initial operations for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery. 2003;134:858-864.
15. Malone JP, Srivastava A, Khardori R. Hyperparathyroidism and multiple endocrine neoplasia. Otolaryngol Clin North Am. 2004;37:715-736, viii.
16. O'Riordain DS, O'Brien T, Grant CS, et al. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery. 1993;114:1031-1039.
17. Obara T, Fujimoto Y, Ito Y. Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: experience by a single surgical team in Japan. Henry Ford Hosp Med J. 1992;40:191-194.
18. Kivlen M, Bartlett DL, Libutti SK, et al. Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery. 2001;130:991-998.
19. Gibril F, Schumann M, Pace A, et al. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore). 2004;83:43- 83.
20. Norton JA, Jensen RT. Current surgical management of Zollinger- Ellison syndrome (ZES) in patients without multiple endocrine neoplasia- type 1 (MEN1). Surg Oncol. 2003;12:145-151.
21. Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med. 1998;243:495-500.
22. Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med. 1995;46:395- 411.
23. Norton JA, Cornelius MJ, Doppman JL, et al. Effect of parathyroidectomy in patients with hyperparathyroidism and Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1: a prospective study. Surgery. 1987;102:958 -996.
24. Trudeau W, McGuigan JE. Effects of calcium on serum gastrin levels in the Zollinger-Ellison syndrome. N Engl J Med. 1969;281:862- 866.
25. McCarthy D, Peiken SR, Lopatin RN, et al. Hyperparathyroidism a reversible cause of cimetidine resistant gastric hypersecretion. Br Med J. 1979;1:1765-1766.
26. Gogel K, Buckman MT, Cadieux T, et al. Gastric secretion and hormonal interactions in Multiple Endocrine Neoplasia Type 1. Arch Intern Med. 1985;145:855- 859.
27. Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med. 1998;243:477- 488.
28. Kerr G, Smith R. Hypercalcemia and gastric hypersecretion in the familial endocrine-adenoma syndrome. Lancet. 1967;1:1074 -1077.
29. Turbey W, Passaro E Jr. Hyperparathyroidism in the Zollinger-Ellison syndrome: influence of hypercalcemia on clinical course. Arch Surg. 1972;105:62- 66.
30. Dutta P, Wallace MR, Wrong OM, et al. Familial multiple endocrine adenopathy (primary hyperparathyroidism and Zollinger-Ellison syndrome) in two siblings. Proc R Soc Med. 1968;61:658-660.
31. Christiansen J, Aagaaard P. Parathyroid adenoma and gastric acid secretion. Scand J Gastroenterol. 1972;7:445- 449.
32. Lamers C, Van Tongeren JHM. Serum gastrin response to acute and chronic hypercalcemia in man: studies on the value of calcium stimulated serum gastrin levels in the diagnosis of Zollinger-Ellison syndrome. Eur J Clin Invest. 1977;7:315-317.
33. Wilson S, Singh RB, Kalkhoff RK, et al. Does hyperparathyroidism cause hypergastrinemia? Surgery. 1976;80:231-237.
34. Dent R, James JH, Want CA, et al. Hyperparathyroidism: gastric acid secretion and gastrin. Ann Surg. 1972;176:360 -369.
35. Stevens M, Thirlby RC, Richardson CT. Lack of effect of parathyroidectomy or calcium blockade on serum gastrin concentration and gastric acid secretion in a patient with hyperparathyroidism and Zollinger- Ellison syndrome. Surgery. 1987;101:108 -113.
36. Thompson M, Sanders DJ, Grund ER. The relationship of the serum gastrin and calcium concentrations in patients with multiple endocrine neoplasia type 1. Br J Surg. 1976;63:779 -783.
37. Berna MJ, Hoffmann KM, Long SH, et al. Serum gastrin in Zollinger- Ellison syndrome. II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature: evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore). 2006;85:331-364.
38. Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger- Ellison syndrome. I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85:295-330.
39. Norton JA, Alexander HR, Fraker DL, et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg. 2001;234:495-505; discussion 505-506.
40. Gibril F, Jensen RT. Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep. 2004;6:454-463.
41. Benya RV, Metz DC, Venzon DJ, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. Am J Med 1994;97:436-444.
42. Fishbeyn V, Norton JA, Benya RV, et al. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Intern Med. 1993;119:199 -206.
43. Roy PK, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis - a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore). 2001;80:189 -222.
44. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore). 2000;79: 379-411.
45. Hoffmann KM, Gibril F, Entsuah LK, et al. Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett's esophagus. J Clin Endocrinol Metab. 2006;91:204-212.
46. Tonelli F, Spini S, Tommasi M, et al. Intraoperative parathormone measurement in patients with multiple endocrine neoplasia type I syndrome and hyperparathyroidism. World J Surg. 2000;24:556 -562; discussion 562-563.
47. Alexander HR, Bartlett DL, Venzon DJ, et al. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome. Surgery. 1998;124: 1160-1166.
48. Norton J, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger- Ellison syndrome. N Engl J Med. 1999;341:635- 644.
49. Norton J, Doppman JL, Jensen RT. Curative resection in Zollinger- Ellison syndrome: results of a 10-year prospective study. Ann Surg. 1992;215:8 -18.
50. Norton JA, Alexander HR, Fraker DL, et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg. 2004;239:617- 625; discussion 626.
51. Abou-Saif A, Gibril F, Ojeaburu JV, et al. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer. 2003;98:249 -261.
52. Eberle F, Grun R. Multiple endocrine neoplasia type 1 (MEN1). Ergeb Inn Med Kinderheilkd. 1981;46:76 -149.
53. Lambert LA, Shapiro SE, Lee JE, et al. Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch Surg. 2005;140:374 -382.
54. Dotzenrath C, Cupisti K, Goretzki PE, et al. Long-term biochemical results after operative treatment of primary hyperparathyroidism associated with multiple endocrine neoplasia types I and IIa: is a more or less extended operation essential? Eur J Surg. 2001;167:173-178.
55. Thakker R. Multiple endocrine neoplasia type 1. Endocrinol Metab Clin North Am. 2000;29:541-567.
56. Van Heerden J, Kent RB, Sizemore GW, et al. Primary hyperparathyroidism in patients with multiple endocrine neoplasia syndromes: surgical experience. Arch Surg. 1983;118:533-536.
57. Samaan NA, Ouais S, Ordonez NG, et al. Multiple endocrine neoplasia type 1. Cancer. 1989;64:741-752.
58. Kaczirek K, Prager G, Schindl M, et al. Multiple endocrine neoplasia 1 - current recommendations for diagnosis and treatment. Wien Klin Wochenschr. 2002;114:258 -266.
59. Hellman P, Skogseid B, Oberg K, et al. Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Surgery. 1998;124:993-999.
60. Goudet P, Cougard P, Verges B, et al. Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D'etude des Neoplasies Endocriniennes Multiples Study Group. World J Surg. 2001;25:886-890.
61. Langer P, Wild A, Schilling T, et al. [Multiple endocrine neoplasia type 1. Surgical therapy of primary hyperparathyroidism]. Chirurg. 2004;75: 900-906.
62. Rizzoli R, Green J, Marx SJ. Primary hyperparathyroidism in familial multiple endocrine neoplasia type 1. Am J Med. 1985;78:467- 474.
63. Hellman P, Skogseid B, Juhlin C, et al. Findings and long-term results of parathyroid surgery in the multiple endocrine neoplasia type 1. World J Surg. 1992;16:718 -723.
64. Thompson NW. The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1 patient. J Intern Med. 1995;238:269 -280.
65. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240:757-773.
66. Sheppard B, Norton JA, Doppman JL, et al. Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. Surgery. 1989;106:1108 -1117.
67. MacFarlane M, Fraker DL, Alexander HR, et al. A prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery. 1995;101:738 -745.
68. Feldman AL, Sharaf RN, Skarulis MC, et al. Results of heterotopic parathyroid autotransplantation: a 13-year experience. Surgery. 1999; 126:1042-1048.
69. Cohen M, Dilley WG, Wells SA Jr, et al. Long-term functionality of cryopreserved parathyroid autografts: a 13-year prospective analysis. Surgery. 2005;138:1033-1040.
70. Wells S, Farndon JR, Dale JK, et al. Long-term evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and heterotopic autotransplantation. Ann Surg. 1980;192:451- 458.
71. Malette L, Blevins T, Jordan PH, et al. Autogeneous parathyroid grafts for generalized primary parathyroid hyperplasia. Surgery. 1987;101: 738-745.